Changchun BCHT Biotechnology Co.,Ltd company info

 HomeAbout Us

About Us Certificates Company Show

BCHT was established in March 2004 by the investment of Changchun High-technology Industry Development Property (Group). The company is a high-tech enterprise engaged in research, development, production and marketing of biologics and drugs. BCHT now owns four manufacturing sites which cover 235,000 square meters in total and two R&D centers for vaccine and drug with the most equipped laboratories and pilot plants in the areas over 5000 square meters. For the last few years, the company`s R&D investment exceeds over 120 million RMB.

In 2008, BCHT successfully launched its product Varicella Vaccine, Live in China. In the following years, BCHT continuously committed to improving the product and led in 2010 removal of gelatin from adjuvant and extended the vaccine shelf-life up to 36 months which is the longest one in the world in 2011. These improvements enhanced the vaccine safety and quality, and established BCHT the leading position in varicella vaccine.

Jilin Maifeng Biopharmaceutical Co., Ltd., a subsidiary of BCHT, is devoted to mostly R&D in high density cell culture technique and its application for large scale production. Jilin Maifeng is the first company to develop and apply the self-developed microcarrier bioreactor technology to produce Rabies Vaccine for human use.

Company Info

Business Type : Manufacturer

Product Range : Moulds

Products/Service:Varicella Vaccine,Rabies Vaccine for Human Use,Bulk of Varicella Vaccine,Bulk of Rabies Vaccine,PFS Varicella Vaccine,Exenatide Acetate

Total Employees : 501~1000

Capital (Million US $) : US$0.2Million

Year Established : 2004

Certificate : GMP

Company Address : 1260Huoju Road,Changchun High-tech Zone, Changchun, Jilin, China

Trade Capacity

Trade Information

Incoterm : FOB,CIF

Terms of Payment : L/C,T/T

Peak season lead time:1-3 months

Off season lead time :One month

Annual Sales Volume (Million US $) : US$1 Million - US$2.5 Million